articleTop 10% cited
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patients
European Journal of Cancer · 1998 · Vol. 34(11) · pp. 1715–1720
Yuh Sakata✉(Aomori Prefectural Central Hospital)Atsushi Ohtsu(National Cancer Centre Japan)N Horikoshi(Japanese Foundation For Cancer Research)K Sugimachi(Kyushu University)Yasushi MitachiT Taguchi(Japan Society of Chemotherapy)
Gastric Cancer Management and OutcomesColorectal Cancer Treatments and StudiesMetastasis and carcinoma case studiesTegafurMedicineAdverse effectGastroenterologyCancerInternal medicineToxicityOral administrationPharmacologyDrug
MeSH terms
Administration, OralAdultAgedAntimetabolites, AntineoplasticDrug CombinationsFemaleTegafurHumansMaleMiddle AgedOxonic AcidPyridinesStomach NeoplasmsSurvival AnalysisTreatment Outcome
Citations
564
FWCI
9.64
field-weighted impact
References
30
Percentile
98%
vs. same field & year
Citations per year
Cited by
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
The Lancet Oncology · 2008 · 1,863 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.